イムノアッセイ市場 – 2030年までの世界予測

Immunoassay Market - Global Forecast to 2030

イムノアッセイ市場 - 製品（試薬・キット、分析装置）、技術（ELISA、CLIA、ウェスタンブロット）、検体（血液、唾液、尿）、用途（感染症、内分泌学）、エンドユーザー（病院・診療所、研究所） - 2030年までの世界予測

Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Western Blot), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Laboratories) - Global Forecast to 2030

商品番号 : SMB-19618

出版社	MarketsandMarkets
出版年月	2025年9月
ページ数	494
図表数	635
価格タイプ	シングルユーザライセンス
価格	USD 4,950
種別	英文調査報告書

本調査レポートは、イムノアッセイ市場を製品（試薬、キット、分析装置）、検体（血液、尿、唾液、その他検体）、技術（ELISA、CLIA、IFA、迅速検査、ELISpot、ウェスタンブロッティング、その他）、用途（感染症、血液スクリーニング、腫瘍学、内分泌学、骨・ミネラル疾患、自己免疫疾患、心臓病学、薬物モニタリング・検査、アレルギー診断、新生児スクリーニング、その他）、エンドユーザー（臨床検査室、病院・診療所、血液銀行、在宅ケア施設）、地域（北米、欧州、アジア太平洋、中東・アフリカ、ラテンアメリカ）別に分類しています。本レポートは、免疫測定市場の成長に影響を与える推進要因、抑制要因、機会、課題など、主要な要因に関する詳細な情報を網羅しています。主要業界プレーヤーの詳細な分析を実施し、各社の事業概要、提供製品、主要戦略、買収、提携に関する洞察を提供しています。新製品の発売と承認、そして免疫測定市場に関連する最近の動向も含まれています。本レポートは、イムノアッセイ（免疫測定）市場のエコシステムにおける新興スタートアップ企業の競争環境を網羅しています。

本レポートは、市場リーダー企業と新規参入企業に対し、免疫測定市場全体とそのサブセグメントの収益予測を提供します。これにより、関係者は競争環境を理解し、自社のポジショニングを改善し、効果的な市場開拓戦略を策定するための洞察を得ることができます。さらに、主要な推進要因、制約要因、課題、機会など、市場動向に関する洞察も提供します。

世界のイムノアッセイ市場は、2025年には推定355億米ドル規模に達し、2030年には477億米ドルに達すると予測されています。予測期間中の年平均成長率（CAGR）は6.1%です。この成長を牽引する主な要因としては、慢性疾患および感染症の増加、免疫測定システムにおける継続的な技術進歩、政府の支援政策、そして厳格な規制による薬物・アルコール検査の重要性の高まりなどが挙げられます。

The global immunoassay market is valued at an estimated USD 35.5 billion in 2025 and is projected to reach USD 47.7 billion by 2030, at a CAGR of 6.1% during the forecast period. Key factors driving this growth include the increasing rates of chronic and infectious diseases, continuous technological progress in immunoassay systems, supportive government policies, and a growing emphasis on drug and alcohol testing due to strict regulations.

イムノアッセイ市場 - 2030年までの世界予測 — immunoassay-market-Overview

“The reagents & kits accounted for the largest share of the immunoassay products market.”

On the basis of products, the global immunoassay market is segmented into reagents & kits and analyzers. Reagents & kits represent the most substantial segment in the diagnostic market, primarily due to their frequent application in a wide array of diagnostic assays. The ongoing demand for these consumables is fueled by the increasing global incidence of immunoassay procedures. Furthermore, the introduction of high-performance reagents and kits, which enhance diagnostic precision and operational efficiency, has facilitated their broader adoption and subsequently spurred growth within this sector.

“The chemiluminescence Immunoassay (CLIA) segment is projected to grow at a considerable rate in the immunoassay technology segment during the forecast period.”

The immunoassay market is categorized by technology into ELISA, chemiluminescence immunoassay (CLIA), immunofluorescence assay (IFA), rapid tests, ELISpot, western blotting, and other methods. The CLIA (Chemiluminescent Immunoassays) segment is forecasted to experience substantial growth, largely due to its advanced diagnostic capabilities applicable to both chronic and infectious diseases. When contrasted with conventional methods like ELISA (Enzyme-Linked Immunosorbent Assay) and radioimmunoassays, CLIA demonstrates superior sensitivity, an extended dynamic range, expedited turnaround times, minimized background interference, and enhanced specificity. These attributes make CLIA the preferred choice for clinical diagnostics, particularly in situations demanding high accuracy and reliability.

“Infectious diseases held the largest share of the immunoassay applications market.”

The global immunoassay market is categorized by application into infectious diseases, cardiology, endocrinology, oncology, bone & mineral disorders, autoimmune disorders, blood screening, allergy diagnostics, drug monitoring & testing, newborn screening, and other applicatons. In 2022, the market for diagnostic testing was predominantly influenced by infectious diseases, largely due to the increasing incidence of conditions like HIV/AIDS, hepatitis, malaria, and influenza. The utilization of immunoassays has played a critical role in this trend, as these tests facilitate rapid and precise diagnoses, thereby enhancing the management of global infectious disease outbreaks.

“Asia Pacific is expected to be the fastest-growing region in the immunoassay market.”

The immunoassay market is regionally segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is anticipated to experience the most significant growth during the forecast period. This rapid expansion can be attributed to several interrelated factors: a substantial and expanding patient demographic, an escalating prevalence of chronic diseases, heightened awareness of the importance of early disease detection, and continuous enhancements in healthcare infrastructure in nations such as China, India, and various Southeast Asian countries.

The break-up of the profile of primary participants in the immunoassay market:

By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
By Designation: CXOs and Directors- 30%, Managers- 45%, and Executives- 25%
By Region: North America -35%, Europe – 25%, Asia Pacific -15%, Latin America -10%, Middle East- 10%, and Africa- 5%

The key players in this market are Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher (US), Thermo Fisher Scientific Inc. (US), Revvity (US), Becton, Dickinson and Company (BD) (US), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), bioMérieux (France), QIAGEN (Germany), Sysmex Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Meridian Bioscience (US), Bio-Techne (US), Cellabs (Australia), Abnova Corporation (Taiwan), J. Mitra & Co. Pvt. Ltd. (India), Tosoh Corporation (Japan), Cell Sciences (US), Enzo Biochem (US), Creative Diagnostics (US), Boster Biological Technology (US), Elabscience (US), WAK-Chemie Medical GmbH (Germany), Sera Care (US), Epitope Diagnostics Inc. (US), Kamiya Biomedical Company (US), Gyros Protein Technologies (Sweden), Trivitron Healthcare (India), InBios International Inc. (India), and Maccura Biotechnology Co., Ltd. (China).

Research Coverage:

This research report categorizes the immunoassay market by product (reagents & kits and analyzers), specimen (blood, urine, saliva, and other specimens), technology (ELISA, CLIA, IFA, rapid tests, ELISpot, western blotting, and other technologies), application (infectious diseases, blood screening, oncology, endocrinology, bone & mineral disorders, autoimmune disorders, cardiology, drug monitoring & testing, allergy diagnostics, newborn screening, and other applications), end user (clinical laboratories, hospitals & clinics, blood banks, and home care settings), and region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors such as drivers, restraints, opportunities, and challenges influencing the growth of the immunoassay market. A detailed analysis of the key industry players has been conducted to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, as well as recent developments associated with the immunoassay market, are also included. This report covers the competitive landscape of upcoming startups in the immunoassay market ecosystem.

Key Benefits of Buying the Report:

The report provides market leaders and new entrants with estimates of revenue figures for the overall immunoassay market and its subsegments. It helps stakeholders understand the competitive landscape and gain insights to better position their businesses and develop effective go-to-market strategies. Additionally, the report offers insights into market dynamics, including key drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

Analysis of key drivers (increasing incidence of chronic and infectious diseases and growing awareness about early disease diagnosis, growth in biotechnology and biopharmaceutical industries, supportive government policies, increasing adoption of immunoassay-based poc testing and rapid testing, increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing), restraints (stringent requirements for approval of immunoassay instruments and consumables, technical hurdles of immunoassay kits), opportunities (growth opportunities in emerging economies, importance of companion diagnostics, development of condition-specific biomarkers and tests, integration of microfluidics in immunoassays, improving immunoassay diagnostic technologies), and challenges (design challenges, complexities, and quality of antibodies, dearth of skilled professionals, unfavorable reimbursement scenario, influencing the growth of the immunoassay market
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the immunoassay market.
Market Development: Comprehensive information about lucrative markets – the report analyses the immunoassay market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the immunoassay market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher (US), and Bio-Rad Laboratories, Inc. (US), among others, in the immunoassay market strategies.

1 INTRODUCTION 39

1.1 STUDY OBJECTIVES 39

1.2 MARKET DEFINITION 39

1.3 STUDY SCOPE 40

1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 40

1.3.2 INCLUSIONS & EXCLUSIONS 41

1.3.3 YEARS CONSIDERED 42

1.3.4 CURRENCY CONSIDERED 42

1.4 STAKEHOLDERS 42

1.5 SUMMARY OF CHANGES 43

2 RESEARCH METHODOLOGY 44

2.1 RESEARCH DATA 44

2.1.1 SECONDARY RESEARCH 45

2.1.1.1 Key secondary sources 45

2.1.1.2 Key data from secondary sources 46

2.1.2 PRIMARY RESEARCH 46

2.1.2.1 Key primary sources 47

2.1.2.2 Key objectives of primary research 47

2.1.2.3 Key data from primary sources 48

2.1.2.4 Key industry insights 49

2.2 MARKET SIZE ESTIMATION 51

2.2.1 BOTTOM-UP APPROACH 51

2.2.2 COMPANY PRESENTATIONS & PRIMARY INTERVIEWS 52

2.2.3 TOP-DOWN APPROACH 53

2.3 DATA TRIANGULATION 54

2.4 MARKET SHARE ANALYSIS 55

2.5 STUDY ASSUMPTIONS 55

2.5.1 MARKET ASSUMPTIONS 55

2.5.2 GROWTH RATE ASSUMPTIONS 55

2.6 RESEARCH LIMITATIONS 56

2.6.1 METHODOLOGY-RELATED LIMITATIONS 56

2.6.2 SCOPE-RELATED LIMITATIONS 56

2.7 RISK ANALYSIS 56

3 EXECUTIVE SUMMARY 57

4 PREMIUM INSIGHTS 63

4.1 IMMUNOASSAY MARKET OVERVIEW 63

4.2 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT AND COUNTRY 64

4.3 IMMUNOASSAY MARKET: GEOGRAPHICAL SNAPSHOT 65

4.4 IMMUNOASSAY MARKET: REGIONAL MIX 66

5 MARKET OVERVIEW 67

5.1 INTRODUCTION 67

5.2 MARKET DYNAMICS 67

5.2.1 DRIVERS 68

5.2.1.1 Increasing incidence of chronic and infectious diseases 68

5.2.1.1.1 Increased use of immunoassays in oncology 69

5.2.1.1.2 Rising use of immunoassays in diagnostic applications 70

5.2.1.1.3 High geriatric population 71

5.2.1.2 Increased demand for blood donations in healthcare systems and surgical procedures 72

5.2.1.3 Growth in biotechnology & biopharmaceutical industries 72

5.2.1.4 Increasing adoption of immunoassay-based POC and rapid testing 73

5.2.1.5 Supportive government regulatory policies and initiatives 74

5.2.1.6 Increased consumption of drugs, alcohol, and cannabis 74

5.2.2 RESTRAINTS 75

5.2.2.1 Stringent requirements for approval of immunoassay instruments and consumables 75

5.2.2.2 Technical hurdles of immunoassay kits 75

5.2.3 OPPORTUNITIES 76

5.2.3.1 Increasing growth opportunities in emerging economies 76

5.2.3.2 Focus on importance of companion diagnostics 77

5.2.3.3 Development of condition-specific biomarkers and tests 78

5.2.3.4 Integration of microfluidics in immunoassays 79

5.2.3.5 Improving immunoassay diagnostic technologies 79

5.2.4 CHALLENGES 80

5.2.4.1 Design challenges and low quality of antibodies 80

5.2.4.2 Dearth of skilled professionals 80

5.3 REGULATORY ANALYSIS 80

5.3.1 REGULATORY FRAMEWORK 80

5.3.1.1 North America 80

5.3.1.1.1 US 80

5.3.1.1.2 Canada 82

5.3.1.2 Europe 82

5.3.1.2.1 Russia 83

5.3.1.3 Asia Pacific 83

5.3.1.3.1 Japan 83

5.3.1.3.2 China 85

5.3.1.3.3 India 85

5.3.1.3.4 Indonesia 86

5.3.1.3.5 South Korea 87

5.3.1.4 Middle East 87

5.3.1.4.1 Saudi Arabia 87

5.3.1.5 Latin America 88

5.3.1.5.1 Mexico 88

5.3.1.5.2 Brazil 89

5.3.1.6 Africa 90

5.3.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90

5.4 TECHNOLOGY ANALYSIS 92

5.4.1 KEY TECHNOLOGIES 92

5.4.1.1 ELISA 92

5.4.2 ADJACENT TECHNOLOGIES 92

5.4.2.1 Microfluidics and miniaturized platforms 92

5.4.3 COMPLEMENTARY TECHNOLOGIES 92

5.4.3.1 Lateral flow assays 92

5.5 TRADE ANALYSIS 94

5.5.1 IMPORT DATA FOR HS CODE 382200, 2019–2024 94

5.5.2 EXPORT DATA FOR HS CODE 382200, 2019–2024 95

5.6 PATENT ANALYSIS 96

5.7 VALUE CHAIN ANALYSIS 97

5.8 SUPPLY CHAIN ANALYSIS 98

5.9 ECOSYSTEM ANALYSIS 99

5.9.1 ROLE IN ECOSYSTEM 100

5.10 PORTER’S FIVE FORCES ANALYSIS 101

5.10.1 INTENSITY OF COMPETITIVE RIVALRY 102

5.10.2 BARGAINING POWER OF SUPPLIERS 102

5.10.3 BARGAINING POWER OF BUYERS 102

5.10.4 THREAT OF SUBSTITUTES 102

5.10.5 THREAT OF NEW ENTRANTS 102

5.11 KEY STAKEHOLDERS & BUYING CRITERIA 103

5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 103

5.11.2 KEY BUYING CRITERIA 103

5.12 KEY CONFERENCES & EVENTS, 2025–2026 104

5.13 PRICING ANALYSIS 105

5.13.1 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS,

BY KEY PLAYER, 2022–2024 105

5.13.2 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY ANAYZERS,

BY REGION, 2022–2024 106

5.13.3 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS,

BY TYPE, 2022–2024 107

5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 108

5.15 CASE STUDY ANALYSIS 109

5.15.1 PORTABLE MICROFLUIDIC CHEMILUMINESCENT IMMUNOASSAY TO BE USED FOR RAPID COVID 19 IMMUNITY MONITORING 109

5.15.2 MICROFLUIDIC-BASED IMMUNOASSAY TO HELP IN EARLY CANCER DETECTION 109

5.15.3 LUMINEX-BASED MULTIPLEX IMMUNOASSAY TO AID AUTOIMMUNE DISEASE PROFILING 110

5.16 INVESTMENT & FUNDING SCENARIO 110

5.17 IMPACT OF AI/GEN AI ON IMMUNOASSAY MARKET 111

5.17.1 MARKET POTENTIAL FOR IMMUNOASSAY PRODUCTS 111

5.17.2 FUTURE OF AI/GEN AI IN IMMUNOASSAY MARKET 112

5.18 IMPACT OF 2025 US TARIFF ON IMMUNOASSAY MARKET 113

5.18.1 INTRODUCTION 113

5.18.2 KEY TARIFF RATES 113

5.18.3 PRICE IMPACT ANALYSIS 114

5.18.4 IMPACT ON COUNTRY/REGION 115

5.18.4.1 North America 115

5.18.4.1.1 US 115

5.18.4.2 Europe 115

5.18.4.2.1 Germany 115

5.18.4.2.2 UK and France 115

5.18.4.3 Asia Pacific 116

5.18.4.3.1 China 116

5.18.4.3.2 Japan 116

5.18.4.3.3 India 116

5.18.5 IMPACT ON END-USE INDUSTRIES 116

5.18.5.1 Hospitals & clinics 116

5.18.5.2 Clinical laboratories 117

5.18.5.3 Blood banks 117

5.18.5.4 Home care settings 117

6 IMMUNOASSAY MARKET, BY PRODUCT 118

6.1 INTRODUCTION 119

6.2 REAGENTS & KITS 119

6.2.1 ELISA REAGENTS & KITS 124

6.2.1.1 Increased use of high-throughput screening in drug discovery programs to drive segment 124

6.2.2 RAPID TEST REAGENTS & KITS 127

6.2.2.1 High demand for preliminary screening tests in remote areas to propel segment growth 127

6.2.3 ELISPOT REAGENTS & KITS 130

6.2.3.1 High sensitivity, functionality, and adaptability of ELISpot technology to aid segment growth 130

6.2.4 CLIA REAGENTS & KITS 133

6.2.4.1 Better diagnosis and higher specificity to augment segment growth 133

6.2.5 IFA REAGENTS & KITS 136

6.2.5.1 Better adaptability in clinical diagnostics to support segment growth 136

6.2.6 WESTERN BLOT REAGENTS & KITS 139

6.2.6.1 Western blot reagents & kits to be considered gold standard for infectious disease test result validation 139

6.2.7 OTHER REAGENTS & KITS 142

6.3 ANALYZERS 144

6.3.1 IMMUNOASSAY ANALYZERS MARKET, BY TYPE 148

6.3.1.1 Open-ended systems 149

6.3.1.1.1 Better flexibility and wider availability to drive segment growth 149

6.3.1.2 Closed-ended systems 152

6.3.1.2.1 Higher precision and better automation to fuel segment growth 152

6.3.2 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE 154

6.3.2.1 Rental purchase 155

6.3.2.1.1 Increased convenience and reduced liability to boost segment growth 155

6.3.2.2 Outright purchase 157

6.3.2.2.1 Inflated cost of immunoassay testing technologies to limit market growth 157

7 IMMUNOASSAY MARKET, BY TECHNOLOGY 160

7.1 INTRODUCTION 161

7.2 ELISA 164

7.2.1 BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET 164

7.3 CLIA 168

7.3.1 GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO AID MARKET GROWTH 168

7.4 IFA 171

7.4.1 IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND

NON-BIOLOGICAL MOLECULES 171

7.5 RAPID TESTS 174

7.5.1 FASTER RESULTS AND EASE OF USE TO DRIVE ADOPTION IN POINT-OF-CARE DIAGNOSIS AND EMERGENCY CARE SETTINGS 174

7.6 WESTERN BLOTTING 177

7.6.1 ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO SPUR MARKET GROWTH 177

7.7 ELISPOT 180

7.7.1 HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY TO PROPEL MARKET GROWTH 180

7.8 OTHER TECHNOLOGIES 183

8 IMMUNOASSAY MARKET, BY SPECIMEN 187

8.1 INTRODUCTION 188

8.2 BLOOD 191

8.2.1 HIGH RELIABILITY AND INCREASED NEED DURING SURGICAL PROCEDURES TO AID MARKET GROWTH 191

8.3 SALIVA 194

8.3.1 ADVANCEMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO AUGMENT MARKET GROWTH 194

8.4 URINE 197

8.4.1 INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO FAVOR MARKET GROWTH 197

8.5 OTHER SPECIMENS 200

9 IMMUNOASSAY MARKET, BY APPLICATION 204

9.1 INTRODUCTION 205

9.2 INFECTIOUS DISEASES 208

9.2.1 RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET 208

9.3 ENDOCRINOLOGY 212

9.3.1 RISING INCIDENCE OF DIABETES TO AUGMENT MARKET GROWTH 212

9.4 CARDIOLOGY 215

9.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO SUPPORT MARKET GROWTH 215

9.5 AUTOIMMUNE DISORDERS 219

9.5.1 HIGH INCIDENCE AND PREVALENCE OF AUTOIMMUNE DISEASES TO AUGMENT MARKET GROWTH 219

9.6 ALLERGY DIAGNOSTICS 222

9.6.1 GROWING PREVALENCE OF ALLERGIES TO AID MARKET GROWTH 222

9.7 ONCOLOGY 225

9.7.1 RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO PROPEL MARKET GROWTH 225

9.8 BONE & MINERAL DISORDERS 228

9.8.1 INCREASING PREVALENCE OF OSTEOPOROSIS, VITAMIN D DEFICIENCY, AND ARTHRITIS TO AID MARKET GROWTH 228

9.9 DRUG MONITORING & TESTING 232

9.9.1 RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO ACCELERATE MARKET GROWTH 232

9.10 BLOOD SCREENING 236

9.10.1 RISING EMPHASIS ON BLOOD DONATIONS TO FAVOR MARKET GROWTH 236

9.11 NEWBORN SCREENING 239

9.11.1 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET GROWTH 239

9.12 OTHER APPLICATIONS 243

10 IMMUNOASSAY MARKET, BY END USER 246

10.1 INTRODUCTION 247

10.2 HOSPITALS & CLINICS 250

10.2.1 GROWING PATIENT POPULATION AND RISING TESTING VOLUME TO DRIVE MARKET 250

10.3 CLINICAL LABORATORIES 254

10.3.1 INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET 254

10.4 HOME CARE SETTINGS 257

10.4.1 RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO PROPEL MARKET GROWTH 257

10.5 BLOOD BANKS 260

10.5.1 INCREASING NUMBER OF ACCIDENTS AND RISING DEMAND FOR BLOOD DURING SURGERIES TO SPUR MARKET GROWTH 260

11 IMMUNOASSAY MARKET, BY REGION 264

11.1 INTRODUCTION 265

11.2 NORTH AMERICA 265

11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 266

11.2.2 US 272

11.2.2.1 US to dominate North American immunoassay market during forecast period 272

11.2.3 CANADA 278

11.2.3.1 Increasing government support and rising incidence of chronic diseases to augment market growth 278

11.3 EUROPE 283

11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 283

11.3.2 GERMANY 289

11.3.2.1 High healthcare spending and favorable government initiatives to propel market growth 289

11.3.3 ITALY 294

11.3.3.1 Rising geriatric population and increasing cancer prevalence to spur market growth 294

11.3.4 FRANCE 298

11.3.4.1 Increased use of POC testing and favorable reimbursement policies to boost market growth 298

11.3.5 SPAIN 303

11.3.5.1 Increasing adoption of technologically advanced immunoassay systems to augment market growth 303

11.3.6 UK 307

11.3.6.1 Government support for disease diagnostics and favorable investment scenario to drive market 307

11.3.7 RUSSIA 313

11.3.7.1 Increasing access to quality healthcare and developing pharmaceutical industry to favor market growth 313

11.3.8 REST OF EUROPE 317

11.4 ASIA PACIFIC 322

11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 322

11.4.2 JAPAN 328

11.4.2.1 Increasing investments in healthcare technologies and research activities to fuel market growth 328

11.4.3 CHINA 333

11.4.3.1 Increasing government investments and rising geriatric population to accelerate maket growth 333

11.4.4 INDIA 337

11.4.4.1 Growing medical tourism and improving healthcare infrastructure to propel market growth 337

11.4.5 AUSTRALIA 342

11.4.5.1 Increasing incidence of cancer and rising focus on blood donations to favor market growth 342

11.4.6 SOUTH KOREA 347

11.4.6.1 Rising healthcare spending and increasing research investments to fuel market growth 347

11.4.7 INDONESIA 351

11.4.7.1 High geriatric population and favorable government healthcare policies to accelerate market growth 351

11.4.8 REST OF ASIA PACIFIC 356

11.5 LATIN AMERICA 360

11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 360

11.5.2 BRAZIL 365

11.5.2.1 High incidence of infectious diseases and presence of academic & research institutes to boost market growth 365

11.5.3 MEXICO 370

11.5.3.1 Increasing geriatric population and rising popularity of medical tourism to propel market growth 370

11.5.4 REST OF LATIN AMERICA 374

11.6 MIDDLE EAST & AFRICA 379

11.6.1 LACK OF SKILLED LABORATORY PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT MARKET GROWTH 379

12 COMPETITIVE LANDSCAPE 384

12.1 INTRODUCTION 384

12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 384

12.2.1 OVERVIEW OF KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN IMMUNOASSAY MARKET 384

12.3 REVENUE ANALYSIS, 2020–2024 386

12.4 MARKET SHARE ANALYSIS, 2024 386

12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 388

12.5.1 STARS 388

12.5.2 EMERGING LEADERS 388

12.5.3 PERVASIVE PLAYERS 389

12.5.4 PARTICIPANTS 389

12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 390

12.5.5.1 Company footprint 390

12.5.5.2 Region footprint 391

12.5.5.3 Product footprint 392

12.5.5.4 Specimen footprint 393

12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 394

12.6.1 PROGRESSIVE COMPANIES 394

12.6.2 RESPONSIVE COMPANIES 394

12.6.3 DYNAMIC COMPANIES 394

12.6.4 STARTING BLOCKS 394

12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 396

12.6.5.1 List of key startups/SMEs 396

12.6.5.2 Competitive benchmarking of key startups/SMEs 397

12.7 COMPANY VALUATION & FINANCIAL METRICS 398

12.7.1 FINANCIAL METRICS 398

12.7.2 COMPANY VALUATION 398

12.8 BRAND/PRODUCT COMPARISON 399

12.9 COMPETITIVE SCENARIO 399

12.9.1 PRODUCT LAUNCHES/APPROVALS/ ENHANCEMENTS 399

12.9.2 DEALS 400

13 COMPANY PROFILES 402

13.1 KEY PLAYERS 402

13.1.1 ABBOTT 402

13.1.1.1 Business overview 402

13.1.1.2 Products offered 403

13.1.1.3 Recent developments 405

13.1.1.3.1 Product approvals 405

13.1.1.3.2 Deals 406

13.1.1.3.3 Expansions 407

13.1.1.4 MnM view 407

13.1.1.4.1 Right to win 407

13.1.1.4.2 Strategic choices 407

13.1.1.4.3 Weaknesses & competitive threats 407

13.1.2 F. HOFFMANN-LA ROCHE LTD. 408

13.1.2.1 Business overview 408

13.1.2.2 Products offered 409

13.1.2.3 Recent developments 412

13.1.2.3.1 Product launches and approvals 412

13.1.2.3.2 Deals 412

13.1.2.3.3 Expansions 413

13.1.2.4 MnM view 413

13.1.2.4.1 Right to win 413

13.1.2.4.2 Strategic choices 414

13.1.2.4.3 Weaknesses & competitive threats 414

13.1.3 SIEMENS HEALTHINEERS AG 415

13.1.3.1 Business overview 415

13.1.3.2 Products offered 416

13.1.3.3 Recent developments 418

13.1.3.3.1 Product launches and approvals 418

13.1.3.3.2 Deals 418

13.1.3.3.3 Expansions 419

13.1.3.4 MnM view 420

13.1.3.4.1 Right to win 420

13.1.3.4.2 Strategic choices 420

13.1.3.4.3 Weaknesses & competitive threats 420

13.1.4 DANAHER 421

13.1.4.1 Business overview 421

13.1.4.2 Products offered 422

13.1.4.3 Recent developments 423

13.1.4.3.1 Product launches and approvals 423

13.1.4.3.2 Deals 424

13.1.4.3.3 Expansions 425

13.1.4.4 MnM view 426

13.1.4.4.1 Right to win 426

13.1.4.4.2 Strategic choices 426

13.1.4.4.3 Weaknesses & competitive threats 426

13.1.5 THERMO FISHER SCIENTIFIC INC. 427

13.1.5.1 Business overview 427

13.1.5.2 Products offered 428

13.1.5.3 Recent developments 429

13.1.5.3.1 Product approvals 429

13.1.5.3.2 Deals 430

13.1.5.4 MnM view 430

13.1.5.4.1 Right to win 430

13.1.5.4.2 Strategic choices 431

13.1.5.4.3 Weaknesses & competitive threats 431

13.1.6 REVVITY 432

13.1.6.1 Business overview 432

13.1.6.2 Products offered 433

13.1.6.3 Recent developments 434

13.1.6.3.1 Product approvals 434

13.1.6.3.2 Other developments 435

13.1.7 BECTON, DICKINSON AND COMPANY (BD) 436

13.1.7.1 Business overview 436

13.1.7.2 Products offered 437

13.1.7.3 Recent developments 438

13.1.7.3.1 Expansions 438

13.1.8 DIASORIN S.P.A. 439

13.1.8.1 Business overview 439

13.1.8.2 Products offered 440

13.1.8.3 Recent developments 442

13.1.8.3.1 Product launches and approvals 442

13.1.8.3.2 Deals 443

13.1.9 BIO-RAD LABORATORIES, INC. 444

13.1.9.1 Business overview 444

13.1.9.2 Products offered 445

13.1.9.3 Recent developments 447

13.1.9.3.1 Product launches 447

13.1.9.3.2 Deals 448

13.1.10 QUIDELORTHO CORPORATION 449

13.1.10.1 Business overview 449

13.1.10.2 Products offered 450

13.1.10.3 Recent developments 453

13.1.10.3.1 Product approvals 453

13.1.10.3.2 Deals 453

13.1.10.3.3 Expansions 454

13.1.11 BIOMÉRIEUX 455

13.1.11.1 Business overview 455

13.1.11.2 Products offered 456

13.1.11.3 Recent developments 457

13.1.11.3.1 Product launches and approvals 457

13.1.11.3.2 Deals 458

13.1.12 QIAGEN 459

13.1.12.1 Business overview 459

13.1.12.2 Products offered 460

13.1.12.3 Recent developments 461

13.1.12.3.1 Deals 461

13.1.13 SYSMEX CORPORATION 462

13.1.13.1 Business overview 462

13.1.13.2 Products offered 464

13.1.13.3 Recent developments 464

13.1.13.3.1 Deals 464

13.1.13.3.2 Expansions 465

13.1.14 AGILENT TECHNOLOGIES, INC. 467

13.1.14.1 Business overview 467

13.1.14.2 Products offered 468

13.1.14.3 Recent developments 469

13.1.14.3.1 Product launches and approvals 469

13.1.14.3.2 Deals 469

13.1.14.3.3 Other developments 470

13.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 471

13.1.15.1 Business overview 471

13.1.15.2 Products offered 472

13.2 OTHER PLAYERS 473

13.2.1 MERCK KGAA 473

13.2.2 MERIDIAN BIOSCIENCE 474

13.2.3 BIO-TECHNE 475

13.2.4 CELLABS 476

13.2.5 ABNOVA CORPORATION 477

13.2.6 J. MITRA & CO. PVT. LTD. 477

13.2.7 TOSOH CORPORATION (TOSOH BIOSCIENCES) 478

13.2.8 CELL SCIENCES 478

13.2.9 ENZO BIOCHEM INC. 479

13.2.10 CREATIVE DIAGNOSTICS 480

13.2.11 BOSTER BIOLOGICAL TECHNOLOGY 480

13.2.12 ELABSCIENCE BIONOVATON INC. 481

13.2.13 WAK-CHEMIE MEDICAL GMBH 481

13.2.14 SERA CARE 482

13.2.15 EPITOPE DIAGNOSTICS, INC. 482

13.2.16 KAMIYA BIOMEDICAL COMPANY 483

13.2.17 GYROS PROTEIN TECHNOLOGIES AB 483

13.2.18 TRIVITRON HEALTHCARE 484

13.2.19 INBIOS INTERNATIONAL, INC. 484

13.2.20 MACCURA BIOTECHNOLOGY CO., LTD. 485

14 APPENDIX 486

14.1 DISCUSSION GUIDE 486

14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 490

14.3 CUSTOMIZATION OPTIONS 492

14.4 RELATED REPORTS 492

LIST OF TABLES

TABLE 1 IMMUNOASSAY MARKET: INCLUSIONS & EXCLUSIONS 41

TABLE 2 IMMUNOASSAY MARKET: KEY DATA FROM PRIMARY SOURCES 48

TABLE 3 IMMUNOASSAY MARKET: MARKET ASSUMPTIONS 55

TABLE 4 IMMUNOASSAY MARKET: RISK ANALYSIS 56

TABLE 5 INCREASING INCIDENCE OF CANCER, BY REGION,

2020 VS. 2030 VS. 2040 (MILLION) 69

TABLE 6 PROJECTED NUMBER OF CANCER PATIENTS, BY CANCER TYPE,

2015 VS. 2018 VS. 2035 (UNITS) 70

TABLE 7 DETECTION TIME OF DRUG OR DRUG CLASS IN URINE TESTING 70

TABLE 8 ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION, BY REGION,

2022 VS. 2030 VS. 2050 71

TABLE 9 RECENT DEVELOPMENTS IN IMMUNOASSAY MARKET, 2021–2023 77

TABLE 10 NEW TESTS LAUNCHED BY KEY PLAYERS, 2021–2023 78

TABLE 11 LAB-ON-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY KEY PLAYERS 79

TABLE 12 US: CLASSIFICATION AND RISK LEVEL OF IMMUNOASSAY PRODUCTS 81

TABLE 13 EUROPE: CLASSIFICATION AND RISK LEVEL OF IN-VIRTO DIAGNOSTIC DEVICES 82

TABLE 14 RUSSIA: CLASSIFICATION AND RISK LEVEL OF IN-VIRTO DIAGNOSTIC DEVICES 83

TABLE 15 JAPAN: CLASSIFICATION OF IN-VIRTO DIAGNOSTIC REAGENTS 84

TABLE 16 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85

TABLE 17 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 85

TABLE 18 INDONESIA: REGISTRATION PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 86

TABLE 19 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 87

TABLE 20 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 88

TABLE 21 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 89

TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90

TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91

TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91

TABLE 25 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91

TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92

TABLE 27 CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES 93

TABLE 28 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES

IN IMMUNOASSAY MARKET 94

TABLE 29 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION) 95

TABLE 30 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION) 95

TABLE 31 IMMUNOASSAY MARKET: ROLE IN ECOSYSTEM 100

TABLE 32 IMMUNOASSAY MARKET: PORTER’S FIVE FORCES 101

TABLE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 103

TABLE 34 KEY BUYING CRITERIA, BY END USER 104

TABLE 35 IMMUNOASSAY MARKET: LIST OF KEY CONFERENCES & EVENTS,

JANUARY 2025–DECEMBER 2026 104

TABLE 36 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 105

TABLE 37 AVERAGE SELLING PRICE TREND OF CLINICAL IMMUNOASSAY ANALYZERS,

BY REGION, 2022–2024 (USD) 106

TABLE 38 AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE,

2022–2024 (USD) 107

TABLE 39 CASE STUDY 1: PORTABLE MICROFLUIDIC CHEMILUMINESCENT IMMUNOASSAY TO BE USED FOR RAPID COVID 19 IMMUNITY MONITORING 109

TABLE 40 CASE STUDY 2: MICROFLUIDIC-BASED IMMUNOASSAY TO HELP IN EARLY

CANCER DETECTION 109

TABLE 41 CASE STUDY 3: LUMINEX-BASED MULTIPLEX IMMUNOASSAY TO AID AUTOIMMUNE DISEASE PROFILING 110

TABLE 42 US ADJUSTED RECIPROCAL TARIFF RATES 113

TABLE 43 IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 119

TABLE 44 KEY REAGENTS & KITS AVAILABLE IN MARKET 120

TABLE 45 IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION,

2023–2030 (USD MILLION) 121

TABLE 46 IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 121

TABLE 47 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 122

TABLE 48 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 122

TABLE 49 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 123

TABLE 50 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 123

TABLE 51 ELISA REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 125

TABLE 52 NORTH AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 125

TABLE 53 EUROPE: ELISA REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 126

TABLE 54 ASIA PACIFIC: ELISA REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 126

TABLE 55 LATIN AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 127

TABLE 56 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 128

TABLE 57 NORTH AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 128

TABLE 58 EUROPE: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 129

TABLE 59 ASIA PACIFIC: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 129

TABLE 60 LATIN AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 130

TABLE 61 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 131

TABLE 62 NORTH AMERICA: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 131

TABLE 63 EUROPE: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 132

TABLE 64 ASIA PACIFIC: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 132

TABLE 65 LATIN AMERICA: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 133

TABLE 66 CLIA REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 134

TABLE 67 NORTH AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 134

TABLE 68 EUROPE: CLIA REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 135

TABLE 69 ASIA PACIFIC: CLIA REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 135

TABLE 70 LATIN AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 136

TABLE 71 IFA REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 136

TABLE 72 NORTH AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 137

TABLE 73 EUROPE: IFA REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 137

TABLE 74 ASIA PACIFIC: IFA REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 138

TABLE 75 LATIN AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 138

TABLE 76 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION,

2023–2030 (USD MILLION) 139

TABLE 77 NORTH AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140

TABLE 78 EUROPE: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 140

TABLE 79 ASIA PACIFIC: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 141

TABLE 80 LATIN AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 141

TABLE 81 OTHER REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 142

TABLE 82 NORTH AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 142

TABLE 83 EUROPE: OTHER REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 143

TABLE 84 ASIA PACIFIC: OTHER REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 143

TABLE 85 LATIN AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 144

TABLE 86 KEY ANALYZERS AVAILABLE IN MARKET 145

TABLE 87 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2023–2030 (USD MILLION) 146

TABLE 88 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 146

TABLE 89 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 147

TABLE 90 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 147

TABLE 91 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 148

TABLE 92 IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 149

TABLE 93 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2023–2030 (USD MILLION) 149

TABLE 94 NORTH AMERICA: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 150

TABLE 95 EUROPE: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 150

TABLE 96 ASIA PACIFIC: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 151

TABLE 97 LATIN AMERICA: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 151

TABLE 98 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2023–2030 (USD MILLION) 152

TABLE 99 NORTH AMERICA: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 152

TABLE 100 EUROPE: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 153

TABLE 101 ASIA PACIFIC: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 153

TABLE 102 LATIN AMERICA: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 154

TABLE 103 IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 154

TABLE 104 RENTAL PURCHASE MARKET, BY REGION, 2023–2030 (USD MILLION) 155

TABLE 105 NORTH AMERICA: RENTAL PURCHASE MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 155

TABLE 106 EUROPE: RENTAL PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156

TABLE 107 ASIA PACIFIC: RENTAL PURCHASE MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 156

TABLE 108 LATIN AMERICA: RENTAL PURCHASE MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 157

TABLE 109 OUTRIGHT PURCHASE MARKET, BY REGION, 2023–2030 (USD MILLION) 157

TABLE 110 NORTH AMERICA: OUTRIGHT PURCHASE MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 158

TABLE 111 EUROPE: OUTRIGHT PURCHASE MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 158

TABLE 112 ASIA PACIFIC: OUTRIGHT PURCHASE MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 159

TABLE 113 LATIN AMERICA: OUTRIGHT PURCHASE MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 159

TABLE 114 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 161

TABLE 115 IMMUNOASSAY TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION) 161

TABLE 116 NORTH AMERICA: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 162

TABLE 117 EUROPE: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 162

TABLE 118 ASIA PACIFIC: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 163

TABLE 119 LATIN AMERICA: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 163

TABLE 120 KEY ELISA TECHNOLOGIES AVAILABLE IN MARKET 164

TABLE 121 IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2023–2030 (USD MILLION) 165

TABLE 122 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,

2023–2030 (USD MILLION) 166

TABLE 123 EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,

2023–2030 (USD MILLION) 166

TABLE 124 ASIA PACIFIC: IMMUNOASSAY MARKET ELISA, BY COUNTRY,

2023–2030 (USD MILLION) 167

TABLE 125 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY,

2023–2030 (USD MILLION) 167

TABLE 126 IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2023–2030 (USD MILLION) 169

TABLE 127 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,

2023–2030 (USD MILLION) 169

TABLE 128 EUROPE: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,

2023–2030 (USD MILLION) 170

TABLE 129 ASIA PACIFIC: IMMUNOASSAY MARKET CLIA, BY COUNTRY,

2023–2030 (USD MILLION) 170

TABLE 130 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY,

2023–2030 (USD MILLION) 171

TABLE 131 IMMUNOASSAY MARKET FOR IFA, BY REGION, 2023–2030 (USD MILLION) 172

TABLE 132 NORTH AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,

2023–2030 (USD MILLION) 172

TABLE 133 EUROPE: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,

2023–2030 (USD MILLION) 173

TABLE 134 ASIA PACIFIC: IMMUNOASSAY MARKET IFA, BY COUNTRY,

2023–2030 (USD MILLION) 173

TABLE 135 LATIN AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY,

2023–2030 (USD MILLION) 174

TABLE 136 KEY RAPID TESTS AVAILABLE IN MARKET 174

TABLE 137 IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION,

2023–2030 (USD MILLION) 175

TABLE 138 NORTH AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023–2030 (USD MILLION) 175

TABLE 139 EUROPE: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,

2023–2030 (USD MILLION) 176

TABLE 140 ASIA PACIFIC: IMMUNOASSAY MARKET RAPID TESTS, BY COUNTRY,

2023–2030 (USD MILLION) 176

TABLE 141 LATIN AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY,

2023–2030 (USD MILLION) 177

TABLE 142 KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET 177

TABLE 143 IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION,

2023–2030 (USD MILLION) 178

TABLE 144 NORTH AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING,

BY COUNTRY, 2023–2030 (USD MILLION) 178

TABLE 145 EUROPE: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY,

2023–2030 (USD MILLION) 179

TABLE 146 ASIA PACIFIC: IMMUNOASSAY MARKET WESTERN BLOTTING, BY COUNTRY,

2023–2030 (USD MILLION) 179

TABLE 147 LATIN AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023–2030 (USD MILLION) 180

TABLE 148 IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2023–2030 (USD MILLION) 181

TABLE 149 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY,

2023–2030 (USD MILLION) 181

TABLE 150 EUROPE: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY,

2023–2030 (USD MILLION) 182

TABLE 151 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY,

2023–2030 (USD MILLION) 182

TABLE 152 LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY,

2023–2030 (USD MILLION) 183

TABLE 153 IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION,

2023–2030 (USD MILLION) 184

TABLE 154 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,

BY COUNTRY, 2023–2030 (USD MILLION) 184

TABLE 155 EUROPE: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 185

TABLE 156 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 185

TABLE 157 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES,

BY COUNTRY, 2023–2030 (USD MILLION) 186

TABLE 158 IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 188

TABLE 159 IMMUNOASSAY SPECIMEN MARKET, BY REGION, 2023–2030 (USD MILLION) 188

TABLE 160 NORTH AMERICA: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 189

TABLE 161 EUROPE: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 189

TABLE 162 ASIA PACIFIC: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 190

TABLE 163 LATIN AMERICA: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 190

TABLE 164 IMMUNOASSAY MARKET FOR BLOOD, BY REGION, 2023–2030 (USD MILLION) 192

TABLE 165 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY,

2023–2030 (USD MILLION) 192

TABLE 166 EUROPE: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY,

2023–2030 (USD MILLION) 193

TABLE 167 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY,

2023–2030 (USD MILLION) 193

TABLE 168 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY,

2023–2030 (USD MILLION) 194

TABLE 169 IMMUNOASSAY MARKET FOR SALIVA, BY REGION, 2023–2030 (USD MILLION) 195

TABLE 170 NORTH AMERICA: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY,

2023–2030 (USD MILLION) 195

TABLE 171 EUROPE: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY,

2023–2030 (USD MILLION) 196

TABLE 172 ASIA PACIFIC: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY,

2023–2030 (USD MILLION) 196

TABLE 173 LATIN AMERICA: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY,

2023–2030 (USD MILLION) 197

TABLE 174 IMMUNOASSAY MARKET FOR URINE, BY REGION, 2023–2030 (USD MILLION) 198

TABLE 175 NORTH AMERICA: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY,

2023–2030 (USD MILLION) 198

TABLE 176 EUROPE: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY,

2023–2030 (USD MILLION) 199

TABLE 177 ASIA PACIFIC: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY,

2023–2030 (USD MILLION) 199

TABLE 178 LATIN AMERICA: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY,

2023–2030 (USD MILLION) 200

TABLE 179 IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION,

2023–2030 (USD MILLION) 201

TABLE 180 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023–2030 (USD MILLION) 201

TABLE 181 EUROPE: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY,

2023–2030 (USD MILLION) 202

TABLE 182 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023–2030 (USD MILLION) 202

TABLE 183 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023–2030 (USD MILLION) 203

TABLE 184 IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 205

TABLE 185 IMMUNOASSAY APPLICATION MARKET, BY REGION, 2023–2030 (USD MILLION) 206

TABLE 186 NORTH AMERICA: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 206

TABLE 187 EUROPE: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 207

TABLE 188 ASIA PACIFIC: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 207

TABLE 189 LATIN AMERICA: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 208

TABLE 190 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION,

2023–2030 (USD MILLION) 209

TABLE 191 NORTH AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION) 210

TABLE 192 EUROPE: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 210

TABLE 193 ASIA PACIFIC: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 211

TABLE 194 LATIN AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION) 211

TABLE 195 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION,

2023–2030 (USD MILLION) 212

TABLE 196 NORTH AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 213

TABLE 197 EUROPE: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY,

2023–2030 (USD MILLION) 213

TABLE 198 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 214

TABLE 199 LATIN AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 214

TABLE 200 KEY PRODUCTS AVAILABLE FOR CARDIOLOGY APPLICATIONS 216

TABLE 201 IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION,

2023–2030 (USD MILLION) 216

TABLE 202 NORTH AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 217

TABLE 203 EUROPE: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,

2023–2030 (USD MILLION) 217

TABLE 204 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,

2023–2030 (USD MILLION) 218

TABLE 205 LATIN AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY,

2023–2030 (USD MILLION) 218

TABLE 206 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION,

2023–2030 (USD MILLION) 219

TABLE 207 NORTH AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION) 220

TABLE 208 EUROPE: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 220

TABLE 209 ASIA PACIFIC: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION) 221

TABLE 210 LATIN AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION) 221

TABLE 211 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION,

2023–2030 (USD MILLION) 222

TABLE 212 NORTH AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,

BY COUNTRY, 2023–2030 (USD MILLION) 223

TABLE 213 EUROPE: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 223

TABLE 214 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 224

TABLE 215 LATIN AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS,

BY COUNTRY, 2023–2030 (USD MILLION) 224

TABLE 216 INCREASING INCIDENCE OF CANCER, BY REGION,

2021 VS. 2030 VS. 2040 (MILLION) 225

TABLE 217 IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION) 226

TABLE 218 NORTH AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION) 226

TABLE 219 EUROPE: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION) 227

TABLE 220 ASIA PACIFIC: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION) 227

TABLE 221 LATIN AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION) 228

TABLE 222 KEY PRODUCTS AVAILABLE FOR BONE & MINERAL DISORDERS 229

TABLE 223 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION,

2023–2030 (USD MILLION) 230

TABLE 224 NORTH AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION) 230

TABLE 225 EUROPE: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION) 231

TABLE 226 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION) 231

TABLE 227 LATIN AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION) 232

TABLE 228 KEY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 233

TABLE 229 KEY IMMUNOASSAY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING 233

TABLE 230 IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY REGION,

2023–2030 (USD MILLION) 234

TABLE 231 NORTH AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023–2030 (USD MILLION) 234

TABLE 232 EUROPE: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,

BY COUNTRY, 2023–2030 (USD MILLION) 235

TABLE 233 ASIA PACIFIC: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,

BY COUNTRY, 2023–2030 (USD MILLION) 235

TABLE 234 LATIN AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING,

BY COUNTRY, 2023–2030 (USD MILLION) 236

TABLE 235 IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION,

2023–2030 (USD MILLION) 237

TABLE 236 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 237

TABLE 237 EUROPE: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY,

2023–2030 (USD MILLION) 238

TABLE 238 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 238

TABLE 239 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 239

TABLE 240 KEY PRODUCTS AVAILABLE FOR NEWBORN SCREENING 239

TABLE 241 IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION,

2023–2030 (USD MILLION) 240

TABLE 242 NORTH AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING,

BY COUNTRY, 2023–2030 (USD MILLION) 241

TABLE 243 EUROPE: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 241

TABLE 244 ASIA PACIFIC: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023–2030 (USD MILLION) 242

TABLE 245 LATIN AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING,

BY COUNTRY, 2023–2030 (USD MILLION) 242

TABLE 246 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION,

2023–2030 (USD MILLION) 243

TABLE 247 NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION) 244

TABLE 248 EUROPE: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 244

TABLE 249 ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 245

TABLE 250 LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2023–2030 (USD MILLION) 245

TABLE 251 IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 247

TABLE 252 IMMUNOASSAY END USER MARKET, BY REGION, 2023–2030 (USD MILLION) 247

TABLE 253 NORTH AMERICA: IMMUNOASSAY END USER MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 248

TABLE 254 EUROPE: IMMUNOASSAY END USER MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 248

TABLE 255 ASIA PACIFIC: IMMUNOASSAY END USER MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 249

TABLE 256 LATIN AMERICA: IMMUNOASSAY END USER MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 249

TABLE 257 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION,

2023–2030 (USD MILLION) 251

TABLE 258 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2023–2030 (USD MILLION) 252

TABLE 259 EUROPE: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 252

TABLE 260 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 253

TABLE 261 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS,

BY COUNTRY, 2023–2030 (USD MILLION) 253

TABLE 262 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION,

2023–2030 (USD MILLION) 255

TABLE 263 NORTH AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,

BY COUNTRY, 2023–2030 (USD MILLION) 255

TABLE 264 EUROPE: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 256

TABLE 265 ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,

BY COUNTRY, 2023–2030 (USD MILLION) 256

TABLE 266 LATIN AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES,

BY COUNTRY, 2023–2030 (USD MILLION) 257

TABLE 267 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION,

2023–2030 (USD MILLION) 258

TABLE 268 NORTH AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS,

BY COUNTRY, 2023–2030 (USD MILLION) 258

TABLE 269 EUROPE: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 259

TABLE 270 ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION) 259

TABLE 271 LATIN AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS,

BY COUNTRY, 2023–2030 (USD MILLION) 260

TABLE 272 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION,

2023–2030 (USD MILLION) 261

TABLE 273 NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023–2030 (USD MILLION) 261

TABLE 274 EUROPE: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY,

2023–2030 (USD MILLION) 262

TABLE 275 ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY,

2023–2030 (USD MILLION) 262

TABLE 276 LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023–2030 (USD MILLION) 263

TABLE 277 IMMUNOASSAY MARKET, BY REGION, 2023–2030 (USD MILLION) 265

TABLE 278 NORTH AMERICA: KEY MACROINDICATORS 266

TABLE 279 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 268

TABLE 280 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT,

2023–2030 (USD MILLION) 268

TABLE 281 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 269

TABLE 282 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 269

TABLE 283 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 270

TABLE 284 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION) 270

TABLE 285 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN,

2023–2030 (USD MILLION) 271

TABLE 286 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION,

2023–2030 (USD MILLION) 271

TABLE 287 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER,

2023–2030 (USD MILLION) 272

TABLE 288 US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED,

2022–2030 (BILLION UNITS) 273

TABLE 289 US: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 274

TABLE 290 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 274

TABLE 291 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 275

TABLE 292 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 275

TABLE 293 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 276

TABLE 294 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 276

TABLE 295 US: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 277

TABLE 296 US: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 277

TABLE 297 CANADA: ESTIMATED PREVALENCE OF DIABETES, 2024 VS. 2034 278

TABLE 298 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 279

TABLE 299 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 279

TABLE 300 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 280

TABLE 301 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 280

TABLE 302 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 281

TABLE 303 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 281

TABLE 304 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 282

TABLE 305 CANADA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 282

TABLE 306 EUROPE: KEY MACROINDICATORS 284

TABLE 307 EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 284

TABLE 308 EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 285

TABLE 309 EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 285

TABLE 310 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 286

TABLE 311 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 286

TABLE 312 EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 287

TABLE 313 EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 287

TABLE 314 EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 288

TABLE 315 EUROPE: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 288

TABLE 316 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 290

TABLE 317 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 290

TABLE 318 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 291

TABLE 319 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 291

TABLE 320 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION) 292

TABLE 321 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 292

TABLE 322 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 293

TABLE 323 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 293

TABLE 324 ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 294

TABLE 325 ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 295

TABLE 326 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 295

TABLE 327 ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 296

TABLE 328 ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 296

TABLE 329 ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 297

TABLE 330 ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 297

TABLE 331 ITALY: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 298

TABLE 332 FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 299

TABLE 333 FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 299

TABLE 334 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 300

TABLE 335 FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 300

TABLE 336 FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 301

TABLE 337 FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 301

TABLE 338 FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 302

TABLE 339 FRANCE: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 302

TABLE 340 SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 303

TABLE 341 SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 304

TABLE 342 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 304

TABLE 343 SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 305

TABLE 344 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 305

TABLE 345 SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 306

TABLE 346 SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 306

TABLE 347 SPAIN: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 307

TABLE 348 UK: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 309

TABLE 349 UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 309

TABLE 350 UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 310

TABLE 351 UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 310

TABLE 352 UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 311

TABLE 353 UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 311

TABLE 354 UK: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 312

TABLE 355 UK: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 312

TABLE 356 RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 313

TABLE 357 RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 314

TABLE 358 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 314

TABLE 359 RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 315

TABLE 360 RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 315

TABLE 361 RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 316

TABLE 362 RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 316

TABLE 363 RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 317

TABLE 364 REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT,

2023–2030 (USD MILLION) 318

TABLE 365 REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 318

TABLE 366 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 319

TABLE 367 REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 319

TABLE 368 REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION) 320

TABLE 369 REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN,

2023–2030 (USD MILLION) 320

TABLE 370 REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION,

2023–2030 (USD MILLION) 321

TABLE 371 REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER,

2023–2030 (USD MILLION) 321

TABLE 372 ASIA PACIFIC: KEY MACROINDICATORS 322

TABLE 373 ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 324

TABLE 374 ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 324

TABLE 375 ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 325

TABLE 376 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 325

TABLE 377 ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 326

TABLE 378 ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION) 326

TABLE 379 ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 327

TABLE 380 ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION,

2023–2030 (USD MILLION) 327

TABLE 381 ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 328

TABLE 382 JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 329

TABLE 383 JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 329

TABLE 384 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 330

TABLE 385 JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 330

TABLE 386 JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 331

TABLE 387 JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 331

TABLE 388 JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 332

TABLE 389 JAPAN: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 332

TABLE 390 CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 333

TABLE 391 CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 334

TABLE 392 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 334

TABLE 393 CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 335

TABLE 394 CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 335

TABLE 395 CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 336

TABLE 396 CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 336

TABLE 397 CHINA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 337

TABLE 398 INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 338

TABLE 399 INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 339

TABLE 400 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION) 339

TABLE 401 INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 340

TABLE 402 INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 340

TABLE 403 INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 341

TABLE 404 INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 341

TABLE 405 INDIA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 342

TABLE 406 AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 343

TABLE 407 AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 343

TABLE 408 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 344

TABLE 409 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 344

TABLE 410 AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION) 345

TABLE 411 AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 345

TABLE 412 AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION,

2023–2030 (USD MILLION) 346

TABLE 413 AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 346

TABLE 414 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT,

2023–2030 (USD MILLION) 347

TABLE 415 SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 348

TABLE 416 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 348

TABLE 417 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 349

TABLE 418 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION) 349

TABLE 419 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN,

2023–2030 (USD MILLION) 350

TABLE 420 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION,

2023–2030 (USD MILLION) 350

TABLE 421 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER,

2023–2030 (USD MILLION) 351

TABLE 422 INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 352

TABLE 423 INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 352

TABLE 424 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 353

TABLE 425 INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 353

TABLE 426 INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION) 354

TABLE 427 INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 354

TABLE 428 INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION,

2023–2030 (USD MILLION) 355

TABLE 429 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 355

TABLE 430 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT,

2023–2030 (USD MILLION) 356

TABLE 431 REST OF ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 357

TABLE 432 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 357

TABLE 433 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 358

TABLE 434 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION) 358

TABLE 435 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN,

2023–2030 (USD MILLION) 359

TABLE 436 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION,

2023–2030 (USD MILLION) 359

TABLE 437 REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER,

2023–2030 (USD MILLION) 360

TABLE 438 LATIN AMERICA: KEY MACROINDICATORS 361

TABLE 439 LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY,

2023–2030 (USD MILLION) 361

TABLE 440 LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT,

2023–2030 (USD MILLION) 361

TABLE 441 LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 362

TABLE 442 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 362

TABLE 443 LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION) 363

TABLE 444 LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION) 363

TABLE 445 LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN,

2023–2030 (USD MILLION) 364

TABLE 446 LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION,

2023–2030 (USD MILLION) 364

TABLE 447 LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER,

2023–2030 (USD MILLION) 365

TABLE 448 BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 366

TABLE 449 BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 366

TABLE 450 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 367

TABLE 451 BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 367

TABLE 452 BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 368

TABLE 453 BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 368

TABLE 454 BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 369

TABLE 455 BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 369

TABLE 456 MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 370

TABLE 457 MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE,

2023–2030 (USD MILLION) 371

TABLE 458 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 371

TABLE 459 MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE,

2023–2030 (USD MILLION) 372

TABLE 460 MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 372

TABLE 461 MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION) 373

TABLE 462 MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 373

TABLE 463 MEXICO: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION) 374

TABLE 464 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT,

2023–2030 (USD MILLION) 375

TABLE 465 REST OF LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 375

TABLE 466 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 376

TABLE 467 REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET,

BY PURCHASE MODE, 2023–2030 (USD MILLION) 376

TABLE 468 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION) 377

TABLE 469 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN,

2023–2030 (USD MILLION) 377

TABLE 470 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION,

2023–2030 (USD MILLION) 378

TABLE 471 REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER,

2023–2030 (USD MILLION) 378

TABLE 472 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT,

2023–2030 (USD MILLION) 380

TABLE 473 MIDDLE EAST & AFRICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 380

TABLE 474 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE,

2023–2030 (USD MILLION) 381

TABLE 475 MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET,

BY PURCHASE MODE, 2023–2030 (USD MILLION) 381

TABLE 476 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY,

2023–2030 (USD MILLION) 382

TABLE 477 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN,

2023–2030 (USD MILLION) 382

TABLE 478 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION,

2023–2030 (USD MILLION) 383

TABLE 479 MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER,

2023–2030 (USD MILLION) 383

TABLE 480 OVERVIEW OF KEY STRATEGIES DEPLOYED BY MAJOR PLAYERS

IN IMMUNOASSAY MARKET 384

TABLE 481 IMMUNOASSAY MARKET: DEGREE OF COMPETITION 387

TABLE 482 IMMUNOASSAY MARKET: REGION FOOTPRINT 391

TABLE 483 IMMUNOASSAY MARKET: PRODUCT FOOTPRINT 392

TABLE 484 IMMUNOASSAY MARKET: SPECIMEN FOOTPRINT 393

TABLE 485 IMMUNOASSAY MARKET: LIST OF KEY STARTUPS/SME PLAYERS 396

TABLE 486 IMMUNOASSAY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/

SME PLAYERS, BY REGION 397

TABLE 487 IMMUNOASSAY MARKET: PRODUCT LAUNCHES/APPROVALS/ENHANCEMENTS, JANUARY 2022–JULY 2025 399

TABLE 488 IMMUNOASSAY MARKET: DEALS, JANUARY 2022–JULY 2025 400

TABLE 489 ABBOTT: COMPANY OVERVIEW 402

TABLE 490 ABBOTT: PRODUCTS OFFERED 403

TABLE 491 ABBOTT: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 405

TABLE 492 ABBOTT: DEALS, JANUARY 2022–JUNE 2025 406

TABLE 493 ABBOTT: EXPANSIONS, JANUARY 2022–JUNE 2025 407

TABLE 494 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 408

TABLE 495 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 409

TABLE 496 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JUNE 2025 412

TABLE 497 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–JUNE 2025 412

TABLE 498 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022–JUNE 2025 413

TABLE 499 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 415

TABLE 500 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED 416

TABLE 501 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JUNE 2025 418

TABLE 502 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–JUNE 2025 418

TABLE 503 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2022–JUNE 2025 419

TABLE 504 DANAHER: COMPANY OVERVIEW 421

TABLE 505 DANAHER: PRODUCTS OFFERED 422

TABLE 506 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 423

TABLE 507 DANAHER: DEALS, JANUARY 2022–JUNE 2025 424

TABLE 508 DANAHER: EXPANSIONS, JANUARY 2022–JUNE 2025 425

TABLE 509 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 427

TABLE 510 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 428

TABLE 511 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS,

JANUARY 2022–JUNE 2025 429

TABLE 512 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JUNE 2025 430

TABLE 513 REVVITY: COMPANY OVERVIEW 432

TABLE 514 REVVITY: PRODUCTS OFFERED 433

TABLE 515 REVVITY: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 434

TABLE 516 REVVITY: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025 435

TABLE 517 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 436

TABLE 518 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 437

TABLE 519 BECTON, DICKINSON AND COMPANY (BD): EXPANSIONS,

JANUARY 2022–JUNE 2025 438

TABLE 520 DIASORIN S.P.A.: COMPANY OVERVIEW 439

TABLE 521 DIASORIN S.P.A.: PRODUCTS OFFERED 440

TABLE 522 DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JUNE 2025 442

TABLE 523 DIASORIN S.P.A.: DEALS, JANUARY 2022–JUNE 2025 443

TABLE 524 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 444

TABLE 525 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 445

TABLE 526 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025 447

TABLE 527 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–JUNE 2025 448

TABLE 528 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 449

TABLE 529 QUIDELORTHO CORPORATION: PRODUCTS OFFERED 450

TABLE 530 QUIDELORTHO CORPORATION: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 453

TABLE 531 QUIDELORTHO CORPORATION: DEALS, JANUARY 2022–JUNE 2025 453

TABLE 532 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025 454

TABLE 533 BIOMÉRIEUX: COMPANY OVERVIEW 455

TABLE 534 BIOMÉRIEUX: PRODUCTS OFFERED 456

TABLE 535 BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025 457

TABLE 536 BIOMÉRIEUX: DEALS, JANUARY 2022–JUNE 2025 458

TABLE 537 QIAGEN: COMPANY OVERVIEW 459

TABLE 538 QIAGEN: PRODUCTS OFFERED 460

TABLE 539 QIAGEN: DEALS, JANUARY 2022–JUNE 2025 461

TABLE 540 SYSMEX CORPORATION: COMPANY OVERVIEW 462

TABLE 541 SYSMEX CORPORATION: PRODUCTS OFFERED 464

TABLE 542 SYSMEX CORPORATION: DEALS, JANUARY 2022–JUNE 2025 464

TABLE 543 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025 465

TABLE 544 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 467

TABLE 545 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 468

TABLE 546 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–JUNE 2025 469

TABLE 547 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–JUNE 2025 469

TABLE 548 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS,

JANUARY 2022–JUNE 2025 470

TABLE 549 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW 471

TABLE 550 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED 472

TABLE 551 MERCK KGAA: COMPANY OVERVIEW 473

TABLE 552 MERIDIAN BIOSCIENCE: COMPANY OVERVIEW 474

TABLE 553 BIO-TECHNE: COMPANY OVERVIEW 475

TABLE 554 CELLABS: COMPANY OVERVIEW 476

TABLE 555 ABNOVA CORPORATION: COMPANY OVERVIEW 477

TABLE 556 J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW 477

TABLE 557 TOSOH CORPORATION (TOSOH BIOSCIENCES): COMPANY OVERVIEW 478

TABLE 558 CELL SCIENCES: COMPANY OVERVIEW 478

TABLE 559 ENZO BIOCHEM INC.: COMPANY OVERVIEW 479

TABLE 560 CREATIVE DIAGNOSTICS: COMPANY OVERVIEW 480

TABLE 561 BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW 480

TABLE 562 ELABSCIENCE BIONOVATON INC.: COMPANY OVERVIEW 481

TABLE 563 WAK-CHEMIE MEDICAL GMBH: COMPANY OVERVIEW 481

TABLE 564 SERA CARE: COMPANY OVERVIEW 482

TABLE 565 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW 482

TABLE 566 KAMIYA BIOMEDICAL COMPANY: COMPANY OVERVIEW 483

TABLE 567 GYROS PROTEIN TECHNOLOGIES AB: COMPANY OVERVIEW 483

TABLE 568 TRIVITRON HEALTHCARE: COMPANY OVERVIEW 484

TABLE 569 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW 484

TABLE 570 MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 485

LIST OF FIGURES

FIGURE 1 IMMUNOASSAY MARKET SEGMENTATION & REGIONAL SCOPE 40

FIGURE 2 IMMUNOASSAY MARKET: YEARS CONSIDERED 42

FIGURE 3 IMMUNOASSAY MARKET: RESEARCH DESIGN 44

FIGURE 4 IMMUNOASSAY MARKET: KEY DATA FROM SECONDARY SOURCES 46

FIGURE 5 IMMUNOASSAY MARKET: KEY PRIMARY SOURCES 47

FIGURE 6 IMMUNOASSAY MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS 49

FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 50

FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,

AND REGION 50

FIGURE 9 IMMUNOASSAY MARKET: COMPANY REVENUE ESTIMATION

(REVENUE SHARE ANALYSIS) 51

FIGURE 10 IMMUNOASSAY MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS) 52

FIGURE 11 IMMUNOASSAY MARKET: TOP-DOWN APPROACH 53

FIGURE 12 IMMUNOASSAY MARKET: DATA TRIANGULATION METHODOLOGY 54

FIGURE 13 IMMUNOASSAY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION) 57

FIGURE 14 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD BILLION) 58

FIGURE 15 IMMUNOASSAY MARKET, BY SPECIMEN, 2025 VS. 2030 (USD BILLION) 59

FIGURE 16 IMMUNOASSAY MARKET, BY APPLICATION, 2025 VS. 2030 (USD BILLION) 60

FIGURE 17 IMMUNOASSAY MARKET, BY END USER, 2025 VS. 2030 (USD BILLION) 61

FIGURE 18 REGIONAL SNAPSHOT OF IMMUNOASSAY MARKET 62

FIGURE 19 FAVORABLE REGULATORY SCENARIO AND HIGH PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 63

FIGURE 20 US AND REAGENTS & KITS COMMANDED LARGEST SHARE OF NORTH AMERICAN IMMUNOASSAY MARKET IN 2024 64

FIGURE 21 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD 65

FIGURE 22 ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING STUDY PERIOD 66

FIGURE 23 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES 67

FIGURE 24 RATE OF INCREASE IN INCIDENCE OF DIABETES GLOBALLY (IN MILLION) 68

FIGURE 25 US: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 81

FIGURE 26 CANADA: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 82

FIGURE 27 JAPAN: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 84

FIGURE 28 INDIA: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 86

FIGURE 29 MEXICO: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 88

FIGURE 30 BRAZIL: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES 90

FIGURE 31 TOP 10 PATENT OWNERS/APPLICANTS IN IMMUNOASSAY MARKET,

JANUARY 2015–DECEMBER 2024 96

FIGURE 32 IMMUNOASSAY MARKET: VALUE CHAIN ANALYSIS 97

FIGURE 33 IMMUNOASSAY MARKET: SUPPLY CHAIN ANALYSIS 98

FIGURE 34 IMMUNOASSAY MARKET: ECOSYSTEM ANALYSIS 99

FIGURE 35 IMMUNOASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS 101

FIGURE 36 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER 103

FIGURE 37 KEY BUYING CRITERIA FOR TOP END USERS 103

FIGURE 38 IMMUNOASSAY MARKET: TRENDS/DISTRUPTIONS IMPACTING

CUSTOMERS’ BUSINESSES 108

FIGURE 39 IMMUNOASSAY MARKET: FUNDING AND NUMBER OF DEALS,

2018−2025 (USD MILLION) 110

FIGURE 40 MARKET POTENTIAL OF AI/GEN AI IN ENHANCING IMMUNOASSAY

DIAGNOSIS AND TREATMENT PLANNING 112

FIGURE 41 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT 267

FIGURE 42 ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT 323

FIGURE 43 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET (2020–2024) 386

FIGURE 44 MARKET SHARE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET (2024) 387

FIGURE 45 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 389

FIGURE 46 IMMUNOASSAY MARKET: COMPANY FOOTPRINT 390

FIGURE 47 IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX

(STARTUPS/SMES), 2024 395

FIGURE 48 EV/EBITDA OF KEY VENDORS, 2025 398

FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS, 2025 398

FIGURE 50 IMMUNOASSAY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 399

FIGURE 51 ABBOTT: COMPANY SNAPSHOT 403

FIGURE 52 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 409

FIGURE 53 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT 416

FIGURE 54 DANAHER: COMPANY SNAPSHOT 422

FIGURE 55 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 428

FIGURE 56 REVVITY: COMPANY SNAPSHOT 433

FIGURE 57 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT 437

FIGURE 58 DIASORIN S.P.A.: COMPANY SNAPSHOT 440

FIGURE 59 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 445

FIGURE 60 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT 450

FIGURE 61 BIOMÉRIEUX: COMPANY SNAPSHOT 456

FIGURE 62 QIAGEN: COMPANY SNAPSHOT 460

FIGURE 63 SYSMEX CORPORATION: COMPANY SNAPSHOT 463

FIGURE 64 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT 468

FIGURE 65 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT 471

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

シングルユーザ	マルチユーザ	コーポレート	エンタープライズサイト
USD4,950	USD6,650	USD8,150	USD10,000

ライセンスタイプ2

シングルユーザ	マルチユーザ	コーポレート	エンタープライズサイト
USD7,150	USD8,500	USD9,650	USD11,000

ライセンスタイプ3

シングルユーザ	マルチユーザ	コーポレート	エンタープライズサイト
USD8,150	お問合せください	お問合せください	お問合せください

ライセンスタイプ4

シングルユーザ	マルチユーザ	コーポレート	エンタープライズサイト
USD9,000	USD10,500	USD12,000	USD13,500

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

シングルユーザ	コーポレート
USD 2,650	USD 4,250

ご購入に関するご案内

価格・納期について

価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
ライセンス
- シングルユーザライセンス
  - 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
  - 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
  - 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
  - 特別ライセンスです。適用範囲についてはお問合せください。
納品形態
- Eメール
納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

Market Research Future 価格表
シングルユーザライセンス	USD 2,950
エンタープライズライセンス	USD 5,250

Market Research Future 価格表
シングルユーザライセンス	USD 4,950
エンタープライズライセンス	USD 7,250

ライセンス別の価格
シングルユーザライセンス	USD 3,500
2-5ユーザライセンス	USD 4,200
サイトライセンス	USD 5,040
エンタープライズライセンス	USD 6,048

ライセンス別の価格
シングルユーザライセンス	USD 5,500
2-5ユーザライセンス	USD 6,600
サイトライセンス	USD 7,920
エンタープライズライセンス	USD 9,504

ライセンス別の価格
シングルユーザライセンス	USD 1,100
コーポレートライセンス	USD 1,500

イムノアッセイ市場 – 2030年までの世界予測

Immunoassay Market - Global Forecast to 2030

Table of Contents

ライセンス別価格表

ご購入に関するご案内

価格・納期について

ご注文方法

その他

最新調査レポート

医療・医薬の最新記事8件

手術用ガウンとドレープ市場規模、シェア、動向、2030年までの世界予測

IVD（体外診断）ラボウェア市場規模、シェア、動向、2030年までの世界予測

医療用レンズ市場調査レポート　2025年

バイオチップ市場規模、シェア、動向、2030年までの世界予測

オリゴヌクレオチド複合体：世界市場シェアとランキング、総売上高と需要予測　2025-2031年

血糖値モニター市場規模、シェア、動向、2030年までの世界予測

スマートホームヘルスケアのマーケットデータ　2025年第4四半期

血管イメージング市場規模、シェア、動向、2030年までの世界予測

ライセンス別の価格
シングルユーザライセンス	USD 1,600
コーポレートライセンス	USD 2,200

ライセンス別の価格
シングルユーザライセンス	USD 2,900
コーポレートライセンス	USD 4,500